title: Efficacy, safety, and pharmacokinetics of once-daily boosted darunavir in pretreated HIV-infected patients.
abstract: OBJECTIVE
  The efficacy and safety of switching to a combined regimen containing darunavir/ritonavir (DRV/r) was investigated in a retrospective study.
  
  
  RESULTS
  Sixty-six experienced patients receiving once-daily DRV/r (900/100 mg) in various regimens were included (median age 51 y; male 82%; Centers for Disease Control and Prevention (CDC) stages B or C 70%). The number of patients with plasma HIV RNA < 50 copies/ml increased from 71% (45/63) at baseline (before switch) to 84% (52/62) at visit 1 (weeks 3-11), and to 92% (60/65) at visit 2 (weeks 12-24). CD4 cells increased from 498 ± 201 cells/mm³ at baseline to 567 ± 232 cells/mm³ by visit 2. Good digestive and metabolic tolerance was observed. The median steady-state DRV plasma concentration, measured 24 ± 4 h after the last drug intake, was 1427 ng/ml. All DRV plasma concentrations were above the protein-binding corrected median effective concentration (EC₅₀) for the wild-type virus (55 ng/ml).
  
  
  CONCLUSIONS
  Once-daily DRV/r (900/100 mg) was efficacious in pretreated patients, with safe responses.
authors.affiliation: Foch Hospital, Suresnes, France.
authors.forename: David
authors.initials: D
authors.lastname: Zucman
authors.forename: P
authors.initials: P
authors.lastname: De Truchis
authors.forename: Gilles
authors.initials: G
authors.lastname: Peytavin
authors.forename: Diane
authors.initials: D
authors.lastname: Descamps
authors.forename: C
authors.initials: C
authors.lastname: Duvivier
authors.forename: L
authors.initials: L
authors.lastname: Tegna
authors.forename: Laurence
authors.initials: L
authors.lastname: Weiss
authors.forename: Jean L
authors.initials: JL
authors.lastname: Delassus
authors.forename: A
authors.initials: A
authors.lastname: Benalycherif
authors.forename: Roland
authors.initials: R
authors.lastname: Landman
mesh_terms: D000328:Adult; D000368:Aged; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D000069454:Darunavir; D005260:Female; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy* / Q000378:metabolism; D017320:HIV Protease Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood* / Q000493:pharmacokinetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D019438:Ritonavir / Q000008:administration & dosage; D013449:Sulfonamides / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood* / Q000493:pharmacokinetics; D019562:Viral Load
chemical_list: D017320:HIV Protease Inhibitors; D013449:Sulfonamides; D019438:Ritonavir; D000069454:Darunavir